Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Biovaxys Technology Corp (CSE: BIOV ) 0.0700 UNCHANGED Last Price Updated: 3:35 PM EDT, May 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 0.0700 Bid (Size) 0.0650 (15,000) Ask (Size) 0.0650 (17,000) Prev. Close 0.0700 Today's Range 0.0700 - 0.0700 52wk Range 0.0100 - 0.1000 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News The Power Play by The Market Herald Releases New Interviews with Reunion Gold Corp, Numinus Wellness, Core Assets, Blockmate Ventures, BioVaxys Tech, Carlyle Commodities and Belmont Resources Discussing Their Latest News April 18, 2023 Via ACCESSWIRE The Power Play by The Market Herald Releases New Interviews with Spey Resources, Melkior Resources and BioVaxys Technology Discussing Their Latest News March 16, 2023 Via ACCESSWIRE Performance YTD +40.00% +40.00% 1 Month N/A N/A 3 Month -12.50% -12.50% 6 Month +55.56% +55.56% 1 Year +180.00% +180.00% More News Read More The Power Play by The Market Herald Releases New Interviews with ApartmentLove, Sirios Resources, Aton Resources, Mountain Boy Minerals and BioVaxys Technology Discussing Their Latest News December 20, 2022 Via ACCESSWIRE BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine December 01, 2022 Via FinancialNewsMedia Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope December 01, 2022 Via FinancialNewsMedia Topics Intellectual Property Exposures Intellectual Property The Power Play by The Market Herald Releases New Interviews with RDARS, Infinity Stone Ventures, BioVaxys Technology, and Sitka Gold Discussing Their Latest News October 06, 2022 Via ACCESSWIRE Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027 October 06, 2022 Via FinancialNewsMedia BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps October 06, 2022 Via FinancialNewsMedia The Power Play by The Market Herald Releases a New Interview with BioVaxys Technology Discussing Their Latest News September 28, 2022 Via ACCESSWIRE Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression May 18, 2022 Via FinancialNewsMedia Topics Death Exposures Death BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement May 18, 2022 Via FinancialNewsMedia Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating April 25, 2022 Via FinancialNewsMedia Topics Intellectual Property Exposures Intellectual Property BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction April 25, 2022 Via FinancialNewsMedia Topics Economy Exposures Supply Chain The Power Play by The Market Herald Releases Interviews With Monarch Mining, Vox, Tocvan Ventures, GeneTether Therapeutics, Peloton Minerals, SWMBRD Sports, and BioVaxys Technology Corp. March 30, 2022 From The Market Herald Via AccessWire Race to Develop Universal ‘Variant-Proof’ Covid Vaccine Involves Several Players March 24, 2022 Via FinancialNewsMedia Exposures COVID-19 Biotech Sector’s Response to Omicron Panic Should be Swift and Effective December 07, 2021 Via FinancialNewsMedia Exposures COVID-19 Anxious World Waits As Covid Vaccine Makers Address Omicron Variant December 07, 2021 Via FinancialNewsMedia Exposures COVID-19 Covid-19 Test Shortage Emphasized by New $70M Plan to Speed Up Authorizations November 09, 2021 Via FinancialNewsMedia Exposures COVID-19 Global COVID-19 Therapeutics Market Size Now Expected To Exceed $25 Billion In 2030 November 09, 2021 Via FinancialNewsMedia Topics Death Exposures COVID-19 Death BioVaxys announces that CoviDTH Demonstrates Safety and Tolerability in Broad Ranging In Vivo Clinical Pathology, Immunology, and Histopathology Evaluation, Supporting Planned Clinical Development of CoviDTH November 09, 2021 Via FinancialNewsMedia Faster, Cheaper, More Reliable COVID-19 Tests Needed for the Unprecedented Demand Ahead October 20, 2021 Via FinancialNewsMedia Exposures COVID-19 BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine October 20, 2021 Via FinancialNewsMedia Topics Intellectual Property Exposures Intellectual Property Scientific Reports Revealing Early Promise for Universal Coronavirus Vaccine October 20, 2021 Via FinancialNewsMedia Exposures COVID-19 New Covid-19 Vaccines Continue to Be Developed by Biotech Firms Seeking to Improve the Jab October 06, 2021 Via FinancialNewsMedia Exposures COVID-19 Big Changes Coming to Covid Testing in Response to Rising Demand Under Latest Mandates September 28, 2021 Via FinancialNewsMedia Exposures COVID-19 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.